Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Kone, Abdoulaye K ^a   Sagara, Issaka ^a   Thera, Mahamadou A ^a   Dicko, Alassane ^a   Guindo, Aldiouma ^a   Diakite, Seidina ^a   Kurantsin Mills, Joseph ^c   Djimde, Abdoulaye ^a   Walcourt, Asikiya ^b   Doumbo, Ogabara ^a  

^a UNIVERSITY OF BAMAKO   (Mali)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS MEFLOQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MALI; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; INFANT; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; INFANT; MALARIA, FALCIPARUM; MALI; MIDDLE AGED; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650211001     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-332     Document Type: Article

References (29)

1. Qinghaosu (artemisinin): an antimalarial drug from China. DL Klayman, Science 1985 228 1049 1055
2. Delaying antimalarial drug resistance with combination chemotherapy. NJ White, Parassitologia 1999 41 301 308
3. Efficacy and safety of artemetherlumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. C Falade M Makanga Z Premji CE Ortmann M Stockmeyer PI de Palacios, Trans R Soc Trop Med Hyg 2005 99 459 467
4. High efficacy of two artemisinin-based combinations (artemether/ lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. CO Falade AO Ogundele BO Yusuf OG Ademowo SM Ladipo, Trop Med Int Health 2008 13 635 643
5. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. C Karema CI Fanello C van Overmeir JP van Geertruyden W van Doren D Ngamije U D'Alessandro, Trans R Soc Trop Med Hyg 2006 100 1105 1111 (Pubitemid 44464010)
6. Influence of hemoglobin E trait on the antimalarial effect of artemisinin derivatives. R Hutagalung P Wilairatana S Looareesuwan GM Brittenham VR Gordeuk, JID 2000 181 1513 1516
7. Decreased sensitivity to artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin Constant Spring erythrocytes. Y Yuthavong P Butthep A Bunyaratvej S Fucharoen, J Clin Invest 1989 83 502 505
8. Haemoglobin S and in vitro chloroquine susceptibility of Plasmodium falciparum. P Nguyen-Dinh RM Parvin, Lancet 1986 2 1278
9. Glucose-6-phosphate dehydrogenase deficiency in red blood cells of East Africans. AC Allison, Nature 1960 186 531 532
10. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A. E Beutler W Kuhl JL Vives-Corrons JT Prchal, Blood 1989 74 2550 2555
11. Plasmodium falciparum: Activity of artemisinin against Plasmodium falciparum cultured in sickle trait hemoglobin AS and normal hemoglobin AA red blood cells. A Walcourt J Kurantsin-Mills BB Adenuga M Loyevsky OO Kassim VR Gordeuk, Expl Parasitol 2008 120 381 384
12. Natural history of Plasmodium falciparum malaria and determining factors of the acquisition of antimalaria immunity in two endemic areas, Dielmo and Ndiop (Senegal). C Rogier, Bull Mem Acad R Med Belg 2000 155 218 226
13. A randomized trial of artesunate-mefloquine versus artemether- lumefantrine for treatment of uncomplicated Plasmodium falciparum Malaria in Mali. I Sagara A Diallo M Kone Coulibaly SI Diawara O Guindo H Maiga BM Mohamed M Sissoko A Dicko A Djimde OK Doumbo, Am J Trop Med Hyg 2008 79 655 661
14. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. PD Crompton B Traore K Kayentao S Doumbo A Ongoiba SA Diakite MA Krause D Doumtabe Y Kone G Weiss CY Huang S Doumbia A Guindo RM Fairhurst LH Miller SK Pierce OK Doumbo, J Infect Dis 2008 198 1265 1275
15. Communicable disease cluster. Severe falciparum malaria. World Health Organization, Trans R Soc Trop Med Hyg 2000 94 1 S90
16. Community permission for medical research in developing countries. DA Diallo OK Doumbo CV Plowe TE Wellems EJ Emanuel SA Hurst, Clinical Infect Dis 2005 41 255 259
17. Website title [Qiagen]. http://www.qiagen.com
18. Website title NEB. http://www.neb.com
19. Website title [Promega]. http://www.promega.com
20. WHO, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated Falciparum malaria. WHO/HTM/RBM/2003.50
21. Present status of understanding on the G6PD deficiency and natural selection. V Tripathy BM Reddy, J Postgrad Med 2007 53 193 202
22. Human erythrocyte glucose-6-phosphate dehydrogenase deficiency. L Luzzatto A Mehta, The metabolic basis of inherited disease McGraw-Hill, New York, Scriver CR, Baudet AL, Sly WS, Valle D, 6 1989 2237 2265
23. Glucose-6-phosphate dehydrogenase deficiency and homozygous sickle cell disease in Congo. JC Bouanga R Mouélé C Préhub H Wajcmanb J Feingold F Galactéros, Hum Hered 1998 48 192 197
24. Host polymorphisms and the incidence of malaria in Ugandan children. S Parikh G Dorsey PJ Rosenthal, Am J Trop Med Hyg 2004 71 750 753
25. Effects of ABO/Rh blood groups, G-6-P-D enzyme activity and haemoglobin genotypes on malaria parasitaemia and parasite density. TK Nkuo-Akenji P Wepngong JF Akoachere, Afr J Health Sci 2004 11 93 97
26. Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. MK Johnson TD Clark D Njama-Meya PJ Rosenthal S Parikh, PLoS One 2009 4 7246 PubMed PMID: 19789650; PubMed Central PMCID: PMC2748715
27. Contribution of humoral immunity to the therapeutic response in falciparum malaria. M Mayxay K Chotivanich S Pukrittayakamee P Newton S Looareesuwan NJ White, Am J Trop Med Hyg 2001 65 918 923
28. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine- pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. I Sagara S Rulisa W Mbacham I Adam K Sissoko H Maiga OB Traore N Dara YT Dicko A Dicko A Djimdé FH Jansen OK Doumbo, Malar J 2009 8 63
29. Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting -thalassemic erythrocytes in vitro: competition in drug accumulation with uninfected erythrocytes. S Kamchonwongpaisan G Chandra-ngam MA Avery Y Yuthavong, J Clin Invest 1994 93 467 473